MSU
ESLA icon

Mizuho Securities USA’s Estrella Immunopharma ESLA Stock Holding History

Mizuho Securities USA’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-88,349
Closed -$866K – 193
2021
Q3 		$866K Buy
+88,349
New +$869K 0.09% 159

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Mizuho Securities USA's ESLA Position: Q4 2021 in Review

Mizuho Securities USA sold out of Estrella Immunopharma (ESLA) in Q4 2021, closing a stake of 88,349 shares — an estimated $866K sold.

Mizuho Securities USA first reported a position in ESLA in Q3 2021 and held it in 1 quarter. The position peaked at $866K in Q3 2021. 19 funds tracked by Wall St. Rank hold ESLA as of Q4 2021.

  • Mizuho Securities USA reported no remaining Estrella Immunopharma position as of Q4 2021 after selling out during the quarter.
  • Mizuho Securities USA sold 88,349 Estrella Immunopharma shares in Q4 2021, an estimated $866K.
  • Mizuho Securities USA first reported a position in Estrella Immunopharma in Q3 2021 and held it in 1 quarter.
  • Mizuho Securities USA's Estrella Immunopharma position peaked at $866K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2021.

Based on Mizuho Securities USA's 13F filing for Q4 2021, filed 28 Jan 2022.